Semaglutide and tirzepatide significantly reduced pulmonary artery pressures and body weight in heart failure patients over 6 months, with weight loss correlating directly to pressure improvements.
r=0.72 correlationWeight loss from GLP-1 drugs correlated strongly with reductions in mean pulmonary artery pressure, suggesting a direct mechanistic link between weight loss and hemodynamic improvement in heart failure.
What the researchers found
In nine heart failure patients with CardioMEMS implants treated with GLP-1 receptor agonists for 6 months, body weight decreased from 123.6 to 117.2 kg (p=0.047). Systolic pulmonary artery pressure fell from 38.9 to 34.0 mmHg (p=0.045), diastolic from 20.0 to 17.8 mmHg (p=0.019), and mean from 27.3 to 24.3 mmHg (p=0.018).
Weight loss correlated significantly with reductions in systolic PAP (r=0.69, p=0.04) and mean PAP (r=0.72, p=0.029). Importantly, guideline-directed medical therapy and loop diuretic doses remained unchanged throughout, suggesting the hemodynamic improvements were attributable to GLP-1 RA treatment rather than changes in background therapy.
Why it matters
Elevated pulmonary artery pressure is a hallmark of worsening heart failure and predicts hospitalizations and death. This is among the first studies to use continuous invasive hemodynamic monitoring to show that GLP-1 drugs improve this key metric. If confirmed in larger trials, this could establish GLP-1 receptor agonists as a hemodynamic therapy for heart failure, beyond their known cardiovascular benefits.
How the study worked
This was a single-center retrospective cohort study of heart failure patients who had CardioMEMS pulmonary artery pressure monitors implanted and subsequently started semaglutide or tirzepatide for at least 6 months. Patients already on GLP-1 RAs before device implantation were excluded. Pulmonary artery pressures were continuously monitored, and correlations between weight change and pressure changes were assessed using Pearson correlation.
What this study cannot tell us
This is a very small retrospective study with only nine patients and no control group. The association between weight loss and pressure reduction could be confounded by other factors. The median semaglutide dose (0.9 mg) was relatively low. Only 6 months of follow-up was available, and it's unclear if benefits persist or continue to improve with longer treatment. The single-center design limits generalizability.
How to read the evidence
This is a very small (n=9) retrospective observational study without a control group. While the use of continuous invasive hemodynamic monitoring (CardioMEMS) provides high-quality pressure data, the study design cannot establish causation. Larger prospective trials are needed.
When this study was published
Published in 2025, this is among the earliest studies using implanted hemodynamic monitors to track GLP-1 drug effects in heart failure, contributing timely data to the rapidly evolving understanding of GLP-1 cardiovascular benefits.
The bigger picture
GLP-1 receptor agonists have already demonstrated cardiovascular mortality benefits in large trials. This study adds a new dimension by showing direct hemodynamic improvement — reduced pulmonary artery pressures — in heart failure patients. As the field explores GLP-1 drugs for heart failure (particularly HFpEF), this mechanistic evidence of pressure reduction through weight loss supports the biological plausibility of benefit.
Questions still open
- Would higher GLP-1 RA doses or longer treatment produce even greater hemodynamic improvements in heart failure?
- Are the pulmonary artery pressure reductions driven entirely by weight loss, or do GLP-1 drugs have direct cardiac effects?
- Could GLP-1 RAs reduce heart failure hospitalizations in patients with elevated pulmonary artery pressures?
Common questions
What is pulmonary artery pressure and why does it matter in heart failure?
How were the pressures measured so precisely?
Read the original research
Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists.
ESC heart failure, 12(4), 2578-2582
Citation
Jiang, Haoran; Wattanachayakul, Phuuwadith; Kittipibul, Veraprapas; Nicolsen, Erika; McVeigh, Todd; Kamneva, Oksana; Fudim, Marat. (2025). Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists.. ESC heart failure, 12(4), 2578-2582. https://doi.org/10.1002/ehf2.15308